2019-nCoV
Conditions
Brief summary
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Interventions
Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
DRUGOseltamivir
Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
DRUGLopinavir/ritonavir
Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Sponsors
Tongji Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 2019-nCoV nucleic acid test was positive. 2. CT of the lung conformed to the manifestation of viral pneumonia.
Exclusion criteria
1. Patients who meet any of the contraindications in the experimental drug labeling 2. Patients who do not want to participate in this clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of disease remission | two weeks | A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2\> 93% or PaO2/FiO2\>300mmHg (1mmHg=0.133Kpa); |
| Time for lung recovery | two weeks | Compare the average time of lung imaging recovery after 2 weeks of treatment in each group. |
Secondary
| Measure | Time frame |
|---|---|
| Rate of lung imaging recovery | two weeks |
| Rate of no fever | two weeks |
| Rate of undetectable viral RNA | two weeks |
| Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery | two weeks |
| Rate of respiratory symptom remission | two weeks |
Countries
China
Contacts
Primary ContactQing Ning, Professor
Backup ContactMeifang Han, Professor
Outcome results
None listed